Pathological precision diagnosis and recent advances in HER2 low and ultralow in breast cancer: a narrative review.

ABSTRACT:

Background and objective

The novel antibody-drug conjugate (ADC) analogues are emerging in the field of human epidermal growth factor receptor 2 (HER2) low and ultralow breast cancer, and accurate screening of patients with HER2 low expression poses a serious challenge to both pathological testing processes and diagnostic assessment. The purpose is to provide some suggestions on how to correctly understand HER2 low and ultralow breast cancer.

Methods

This paper explores the clinicopathological features, immunohistochemical staining and its heterogeneity of HER2 low and ultralow expression breast cancer through literature search.

Key content and findings

This article mainly elaborates on four aspects: the differences in clinical pathological characteristics and prognos

SUBMITTER: Shang J 

PROVIDER: S-EPMC11557157 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature